BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Coherus BioSciences Announces Appointment of George G. Montgomery as Chief Financial Officer


10/22/2012 10:32:15 AM

REDWOOD CITY, Calif., Oct. 22, 2012 /PRNewswire/ -- Coherus BioSciences, Inc. ("Coherus"), a biopharmaceuticals company dedicated to global development and commercialization of biologic therapeutics, announced today that it has appointed George G. Montgomery as Chief Financial Officer. Mr. Montgomery joins Coherus with over 25 years of experience as an investment banker and industry executive in the pharmaceutical and biotechnology sectors.

(Logo: http://photos.prnewswire.com/prnh/20120507/SF01448LOGO)

"George has been contributing to Coherus' success from early on in the company's development. He was instrumental in helping us raise our first institutional round of financing, as well as complete our licensing arrangement with Daiichi Sankyo," said Denny Lanfear, Chief Executive Officer of Coherus. "George has a renowned reputation in the industry as a premier investment banker and strategic advisor for biotech companies. We are thrilled and fortunate to have him join Coherus as CFO, and work with us to move the company's strategic agenda forward."

"Coherus has a unique business and global commercialization model specifically addressing the enormous biosimilar opportunity. Working with the company for the past eighteen months convinced me that all the key factors for success are in place," said Mr. Montgomery. "I am excited to work with the outstanding team at Coherus to help achieve the company's full potential."

Mr. Montgomery joins Coherus with over 25 years of experience in investment banking and industry leadership. Over his career, he has focused on private and public financings, M&A advisory work, divestitures and negotiating strategic partnerships. Most recently, Mr. Montgomery was a Managing Director at Sagent Advisors, LLC. Prior to Sagent, he served as a Managing Director at Montgomery & Co., LLC where he led the firm's healthcare effort and helped open their San Francisco office. During his tenure there, he also served on their Board of Directors and was a member of the executive committee. Prior to Montgomery & Co., he was a Managing Director at JP Morgan H&Q where he led the firm's healthcare efforts on the West Coast. He has also been a Managing Director at Cowen & Company and started his career at Credit Suisse First Boston in 1983. George received his MBA from the Wharton School at the University of Pennsylvania and his BA from Yale College.

About Coherus BioSciences

Coherus BioSciences is an emerging biopharmaceutical company headquartered in the San Francisco Bay Area developing safe, high-quality biosimilar therapeutics. Since its founding in 2010, Coherus has formed global partnerships and developed a pipeline of five product candidates for treating cancer and inflammatory diseases. Led by an experienced team of industry veterans, Coherus is reinventing the business model of developing biologic medicines, from concept to commercialization, so that more people around the world can have greater access to quality therapeutics. For additional information, please visit www.coherus.com.

MEDIA CONTACT
Lana Smith
lsmith@coherus.com

SOURCE Coherus BioSciences



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES